|Mr. David A. Regan||Chief Exec. Officer||164.24k||N/A||N/A|
|Mr. Darren Rowles||Pres & Chief Scientific Officer||132.62k||N/A||1979|
|Mr. Robert William George Randall||CFO & Corp. Sec.||87.4k||N/A||1963|
|Dr. Kulbir Singh||Co-Founder & Head of R&D||N/A||N/A||N/A|
|Dr. Mike McAlduff||Director of R&D & Production and Founder||N/A||N/A||N/A|
|Dr. Gerrard Marangoni||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
Sona Nanotech Inc., nanotechnology life sciences company, manufactures gold nanorod products for diagnostic tests. Its products portfolio comprises Gemini 650NM, Gemini 700NM, Gemini 725NM, Gemini 750NM, Gemini 800NM, Gemini 850NM, Gemini 900NM, Gemini 950NM, and Gemini 1050NM. The company also provides Sona Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic assay for the detection of the spike protein antigen from SARS-CoV-2 in nasopharyngeal swab specimens from individuals, who are suspected of COVID-19. In addition, it offers Gemini and Omni gold nanorods for in-vitro and in-vivo applications, such as lateral flow diagnostics and cell imaging. The company has collaboration agreements with Soma Bioscience Ltd. to produce diagnostic tests using lateral flow assay technology; and Expedeon Ltd to develop multiplex point-of-care and lateral flow assay diagnostic tests. Sona Nanotech Inc. is based in Halifax, Canada.
Sona Nanotech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.